About
Science
- PAM Pathway
- Publications
Pipeline
Clinical Trials
Investors
Careers

Test measuring signaling activity in live patient tumor cells identifies PI3KCA WT patients who may benefit from PIK3 inhibitors

Post navigation

Hyperactive c-Met and ErbB signaling detected in a sub-group of ovarian patient tumors: Patient sub-group may benefit from c-Met and pan-HER combination therapy

Sub-Group of PIK3CA WT breast cancer patients have hyperactive S1P and LPA signaling tumors responsive to PI3K inhibitors: functional signaling test identifies new patient group who may benefit from PI3K inhibitors

Search for:

Recent Posts

Developing first-in-class therapeutics using a 3rd generation diagnostic platform

Recent Comments

Archives

October 2021

Categories

Uncategorized

Meta

Log in
Entries feed
Comments feed
WordPress.org

2800 Campus Dr, Suite 140
Minneapolis, MN 55441

Follow us on

in x

©2026 Celcuity Inc.

Privacy Center Terms of Use Accessibility Statement